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Idiopathic pulmonary ﬁbrosis (IPF) is the most common form of interstitial lung disease
characterized by the persistence of activated myoﬁbroblasts resulting in excessive deposi-
tion of extracellular matrix proteins and profound tissue remodeling. Myoﬁbroblasts have
been shown to arise from interstitial ﬁbroblasts, epithelial to mesenchymal transition
of type II alveolar epithelial cells, and the differentiation of recruited ﬁbrocytes. There
are many mechanisms that are utilized by these cells for survival, proliferation, and
persistent activation including up-regulation of cytokines [i.e., Interleukin 6 (IL-6) and C-C
motif chemokine ligand 21 (CCL21)], cytokine receptors [i.e., Interleukin 6 Receptor 1 (IL-
6R1), Glycoprotein 130 (gp130) and C-C Chemokine Receptor type 7 (CCR7)], and innate
pattern recognition receptors [(PRRs; i.e., Toll Like Receptor 9 (TLR9)]. In this review,
we will discuss the role of the cytokines IL-6 and CCL21, their receptors and the PRR,
TLR9, in ﬁbroblast recruitment, activation, survival, and differentiation into myoﬁbroblasts
in IPF.
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(CCL21)
INTRODUCTION
Interstitial lung diseases (ILD) are a heterogeneous group of non-
neoplastic pulmonary disorders that affect 500,000 people in US
and are thought to result from inﬂammatory and/or aberrant
repairmechanisms in the lung (King,2005). Idiopathic pulmonary
ﬁbrosis (IPF) is the most common clinical form of ILD, with poor
prognosis, median survival at 3–5 years after diagnosis, and no
effective pharmacological intervention (du Bois, 2010). IPF is
characterized histologically by the presence of usual interstitial
pneumonia (UIP), containing ﬁbroblastic foci, which are believed
to be the site of active tissue remodeling due to presence of acti-
vated ﬁbroblasts. The ﬁbrotic triggers in IPF are unknown but it is
speculated that persistent lung injury leads to alveolar epithelial
cell injury and death, and subsequent aberrant repair mecha-
nism(s) ablates the alveolus (Hecker and Thannickal, 2011; Wynn,
2011; Wolters et al., 2013).
The circumstances leading to aberrant repair mechanisms in
IPF are unknown. However, several reports document heteroge-
neous responses of IPF lung ﬁbroblasts to several inﬂammatory
and non-inﬂammatory stimuli. In this report, we will review work
pertaining to the responses of IPF lung ﬁbroblasts to the cytokines,
CCL21 and IL6, and to the pathogen associated molecular pat-
tern (PAMP), hypomethylated CpG DNA (hereon referred to as
CpG-ODN), and its receptor TLR9.
CCR7 AND CCL21
Cytokines have been shown to play a major role in the progres-
sion of pulmonary ﬁbrosis in both mice and human. Chemokines
are a class or chemotactic cytokines that bind to and activate
their receptors to induce cellular activation and migration. Sev-
eral chemokine and chemokine receptors are highly expressed in
IPF lungs and are thought to play a role in ﬁbrogenesis. To this end,
several in vitro, in vivo and ex vivo studies have identiﬁed CCL21
and its receptor CCR7 as important players in the progression of
lung ﬁbrosis.
CCR7 is a member of the G protein coupled receptors that is
activated by its ligands CCL19 [also called EBI1 ligand chemokine
(ELC) and macrophage inﬂammatory protein 3 beta (MIP-
3β)] and CCL21 [also called 6-Ckine, exodus-2, and secondary
lymphoid-tissue chemokine (SLC)]. CCR7 is highly expressed on
T lymphocytes and activated dendritic cells where it was shown
to be important for the migration of these cells into lymphoid
tissues, which express a high concentration of CCL19 and CCL21.
Further, CCL21 has been implicated in the formation of sec-
ondary (i.e., lymph nodes) and tertiary (i.e., bronchoalveolar
lymphoid tissues) lymphoid tissues, with the latter being observed
in IPF lung biopsies (Campbell et al., 1985; Wallace et al., 1996;
Marchal-Somme et al., 2006; Rangel-Moreno et al., 2006). CCR7
has been shown to be utilized by many tumor cells for survival
and lymphatic metastasis [Reviewed in (Fang and Hwang, 2009)].
Recently the expression of CCR7 was observed to be signiﬁ-
cantly increased in the lungs of IPF patients (Choi et al., 2006)
suggesting that this receptor might be involved in the genesis
of IPF.
Gene expression studies performed by Choi et al. (2006) indi-
cated that CCR7 mRNA levels were markedly increased in IPF as
compared to normal lung biopsies in contrast to the CCR7 ligands,
CCL19, and CCL21, which were similar in the two biopsies (Choi
et al., 2006). Histological analysis conﬁrmed the gene expression
studies and indicated that CCR7 was focally expressed in IPF lungs
but not in normal lung biopsies, where there were no detectable
CCR7 staining. Further, CCR7 staining partially co-localized with
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CD45+ cells but not with alpha Smooth Muscle Actin (αSMA)+,
Collagen I+ (COL1), or CD34+ cells suggesting that ﬁbrocytes
did not express this chemokine receptor in the analyzed tissues.
Morphological analysis of the histologically stained sections sug-
gested that CCR7 stainingwas present in ﬁbroblasts,mononuclear,
and epithelial cells (Choi et al., 2006). In a subsequent study,
IPF ﬁbroblasts expressed signiﬁcantly greater levels of CCR7 as
compared to normal lung ﬁbroblasts, conﬁrming the histological
ﬁndings of Choi et al. (2006) and suggesting that these cells might
contribute to the increased expression of CCR7 in IPF (Pierce et al.,
2007a,b).
Under normal conditions, CCR7 is predominately expressed
by T cells, B cells, and dendritic cells; however, its expression was
also observed in several cancers and cancer cell lines where it is
thought to promote cell survival and lymphatic metastasis. Simi-
lar to cancer cells, studies have suggested that IPF lung ﬁbroblasts
might utilize CCR7 for migration into the lungs, proliferation
and survival. Pierce et al. (2007a) have shown that IPF ﬁbroblasts
can migrate to CCL21. Further, this migration was dependent
on the both CCR7 and CCL21 as shown by the inhibition of
migration after the immuno-neutralization of either of these pro-
teins (Pierce et al., 2007a). This study showed that in addition to
promoting cellular migration, CCL21 enhanced ﬁbroblast pro-
liferation, CCL5, and αSMA expression. This was hypothesized
to be due to the enhanced activation of the Mitogen Activated
Protein Kinase (MAPK) and Extracellular signal Related Kinase
1/2 (ERK1/2) pathways by CCL21 in IPF as compared to normal
lung ﬁbroblasts. In another study performed by the same group,
lung ﬁbroblasts were puriﬁed from normal and IPF lung biop-
sies, cultured and then intravenously injected into C.B-17SCID
mice, where they were observed to localize to the lung of these
mice and induce signiﬁcant lung ﬁbrosis 63 days after injection
(Pierce et al., 2007b). Further, IPF ﬁbroblasts induced a signiﬁcant
increase of CCL21, Cathepsin E, MMP-19 and TIMP-1 expres-
sion by other cells in the ﬁbrotic lungs of these mice 63 days
after injection. Immuno-neutralization of CCR7 or CCL21 sig-
niﬁcantly reduced ﬁbrosis in the lungs of IPF ﬁbroblasts injected
C.B-17SCID mice. These studies suggest that IPF ﬁbroblasts uti-
lize CCR7 and CCL21 for migration, survival, proliferation and
activation, in a similar manner as many cancer cells, and that
targeting this chemokine and its receptor therapeutically might
ameliorate IPF.
Several studies have shown that ﬁbrocyte differentiation con-
tributes to ﬁbrosis in several ﬁbrotic diseases by expression and
secretion of Extracellular Matrix (ECM) proteins and differ-
entiation into myoﬁbroblasts, which further contributes to the
accumulation ECM proteins. Fibrocytes are a population of cells
with ﬁbroblast like properties, characterized by their expression
of CD45, CD34, and COL1 (Bucala et al., 1994). These cells are
heterogeneous in nature; they were also reported to express COL3,
vimentin, ﬁbronectin, CD11b, CD80, CD86, and the chemokine
receptors CCR2, CCR7, and CXCR4 (Bucala et al., 1994; Abe et al.,
2001; Schmidt et al., 2003; Phillips et al., 2004). Fibrocytes were
shown to migrate toward CCL21 in an in vitro transwell chemo-
taxis assay (Abe et al., 2001). Checkerboard analysis conﬁrmed
that this migratory response toward CCL21 was chemotactic but
not chemokinetic. Further, following the intravenous injection of
labeledﬁbrocytes inmice, intradermal injectionof CCL21 induced
the recruitment of ﬁbrocytes to the site of injection, conﬁrming
the results observed in the in vitro transwell chemotaxis assay (Abe
et al., 2001).
The role of ﬁbrocytes in IPF is currently controversial; how-
ever, it has been observed that there is a signiﬁcant increase in the
number of circulating ﬁbrocytes in IPF patients (Mehrad et al.,
2007), suggesting that these cells might contribute to this disease.
Using a murine model of lung ﬁbrosis, Phillips et al. (2004) have
identiﬁed several populations of ﬁbrocytes based on their surface
expression of the chemokine receptors CXCR4 and CCR7 in mice,
CD45+ COLI+ CXCR4+ CCR7−, and CD45+ COLI+ CXCR4−
CCR7+. This study indicated that CXCR4+cells are the predomi-
nant population of ﬁbrocytes recruited to ﬁbrotic lungs of mice in
a bleomycin model of lung ﬁbrosis and that neutralizing CXCL12
signiﬁcantly reduced lung ﬁbrosis. This was further supported by
other studies where it was shown that CXCR4+ﬁbrocytes were
the predominant population of ﬁbrocytes in circulation in IPF
patients and that these cells were present in histological sections
from human IPF lung biopsies (Mehrad et al., 2007; Andersson-
Sjöland et al., 2008). Further, a recent study have shown that there
were no differences in the number of ﬁbrocytes recruited into
murine ﬁbrotic lungs in response to bleomycin challenge between
wild type and CCR7-/- mice further supporting that CCR7 might
not be the predominant chemokine receptor required for the
recruitment of ﬁbrocytes into ﬁbrotic lungs in mice (Trujillo et al.,
2010a).
Collectively, these studies suggest thatCCR7 is expressed on IPF
lung ﬁbroblasts and is utilized for their activation, survival, and
proliferation Figure 1. Further, CCR7 is expressed on ﬁbrocytes
but it is not the dominant chemokine receptor utilized by these
cells for their recruitment in murine ﬁbrotic lungs. These studies
suggest that targeting CCR7 and its ligand CCL21 might lead to
reduced ﬁbroblast activation, proliferation, and survival in IPF
and the amelioration of this disease.
IL-6 AND IL-6Rα/GP130
IL6 is a multifunctional cytokine belonging to the IL-6 family
of cytokines, which includes Interleukin 11 (IL-11), oncostatin
M, ciliary neurotrophic factor, leukemia inhibitory factor, and
cardiotrophin-1. The IL-6 family is characterized by signaling
through a commonbroadly expressed receptor, gp130 (also known
as IL6ST, IL6-beta, or CD130), which forms a heterodimer with
a unique alpha chain, such as IL-6Rα for IL-6, to induce either
pro-inﬂammatory or anti-inﬂammatory responses. Several mem-
bers of the IL-6 family of cytokines, including IL-6, IL-11, and
oncostatin M, have been implicated in IPF with the former being
the best-studied member in this disease. In vitro studies indicated
that IL-11 was mitogenic and inhibited Fas induced apoptosis
of lung ﬁbroblasts derived from normal and IPF lung biopsies
(Moodley et al., 2003a,b). Other studies indicated that oncostatin
M was signiﬁcantly increased in bronchoalveolar lavage ﬂuid
(BALF) from IPF patients and in the lungs of bleomycin chal-
lenged mice; and its chronic intranasal administration induced a
ﬁbrotic response in murine lungs, which was independent from
Interleukin 4 (IL-4)/Interleukin 13 (IL-13) and Transforming
Growth Factor-beta (TGF-β) signaling (Richards et al., 2002;
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FIGURE 1 | Overview of the role of CCL21 and its receptor CCR7 in pulmonary fibrosis. Shown is a simpliﬁed overview of the role of CCL21 produced in
ﬁbrotic lungs in the promotion of pulmonary ﬁbrosis via the recruitment and activation of lung ﬁbroblasts and ﬁbrocytes.
Mozaffarian et al., 2008). Further in vitro studies indicated that
oncostatin M was mitogenic, inhibited spontaneous ﬁbroblast
apoptosis, induced COL expression by human lung ﬁbroblasts and
inhibited TGF-β induced αSMA expression by a subset of IPF lung
ﬁbroblasts characterized by the presence of constitutively active
Signal Transducer and Activator of Transcription 3 (STAT3; Scaf-
ﬁdi et al., 2002; Pechkovsky et al., 2012). These studies suggest that
this family of cytokines might contribute to the ﬁbrotic response
in IPF.
Interleukin-6 is expressed and secreted by various cells includ-
ing alveolar macrophages, lung ﬁbroblasts (Shahar et al., 1996),
and ﬁbrocytes (Chesney et al., 1998). Upon binding to its recep-
tor, IL-6 activates the Janus Kinase (JAK)/STAT; (i.e., JAK1/2 and
STAT1/3) and the SH2 domain containing protein tyrosine phos-
phatase SHP-2 andERKMAPKpathways [reviewed in (Kamimura
et al., 2003)]. IL-6 signaling is tightly regulated by various pro-
teins and mechanisms including: (1) Protein inhibitor of activated
STAT (PIAS), which inhibits STAT activation; (2) Suppressor Of
Cytokine Signaling (SOCS), which inhibits JAK signaling; and (3)
Shedding of IL-6Rα to create a soluble decoy receptor. Further,
SHP-2 has been shown to be a negative regulator, by dephos-
phorylating activated JAK and STAT proteins leading to reduced
JAK/STAT signaling, and a positive regulator, by the inhibition
of SOCS binding with JAK thus enhancing JAK/STAT signaling
[Figure 2; reviewed in (Xu and Qu, 2008)].
Due to its multifunctional properties, there is great interest in
dissecting the role of IL-6 in IPF. The concentration of IL-6 was
observed to be signiﬁcantly increased in BALF from IPF patients
as compared to control BALF (Takizawa et al., 1997) suggesting
that this cytokine might be involved in the progression of IPF.
Further, IL-6 was expressed and secreted by alveolar macrophages
and lung ﬁbroblasts in response to TNF-α stimulation (Shahar
et al., 1996). Interestingly, IL-6 inhibited proliferation in nor-
mal lung ﬁbroblasts but was mitogenic to IPF lung ﬁbroblasts
(Moodley et al., 2003b). This was shown to be independent of
gp130 expression and to be due to differential IL-6 signaling in
these two ﬁbroblast populations: in normal lung ﬁbroblasts, IL-6
induced sustained STAT3 signaling leading to increased expres-
sion of the Cyclin Dependent Kinase Inhibitor (CDKI) p19INK4D;
however, in IPF lung ﬁbroblasts, IL-6 induced sustained SHP-
2/ERK MAPK signaling leading to the decreased expression of
the CDKI p27Kip1, increased Cyclin D1 activation, and enhanced
proliferation (Knight et al., 2003).
In a subsequent study, IL-6 induced the resistance of IPF
lung ﬁbroblasts to Fas-induced apoptosis due to the increased
expression of the anti-apoptotic protein BCL-2, in contrast to
IL-6 stimulated normal lung ﬁbroblasts, which were more sen-
sitive to Fas-induced apoptosis due to the increased expression
of the pro-apoptotic protein Bax (Moodley et al., 2003a). Inter-
estingly, the increased BCL-2 and decreased Bax expression in
IPF and normal lung ﬁbroblasts, respectively, were shown to
be dependent on STAT3 suggesting that STAT3 activation in
these ﬁbroblasts is differentially regulated (Moodley et al., 2003a).
This was supported by another study, which indicated that there
was a signiﬁcant decrease in the expression of the JAK/STAT3
inhibitor, SOCS1, in IPF as compared to normal lung ﬁbroblasts,
which was correlated with increased COL1 expression by IPF lung
ﬁbroblasts (Shoda et al., 2007). A role of SOCS1 in lung ﬁbro-
sis was supported by another study using SOCS1-haplodeﬁcient
(+/−) mice in a bleomycin induced model of lung ﬁbrosis
(Nakashima et al., 2008). In this study, bleomycin challenged
SOCS1-haplodeﬁcient mice developed signiﬁcantly increased pul-
monary ﬁbrosis as compared to wild type mice further sup-
porting that altered gp130 signaling can exacerbate a ﬁbrotic
response.
Recently, Pechkovsky et al. (2012) identiﬁed a population of
ﬁbroblasts from IPF lung biopsies which were characterized by
the constitutive activation of STAT3. These ﬁbroblasts had lower
proliferation rates, decreased αSMA, Thy-1, and β3 integrin
expression as compared to normal lung ﬁbroblasts and were not
localized in αSMA rich ﬁbroblastic foci, but were localized near
areas of dense ﬁbrosis. This study suggests that there are dif-
ferent populations of ﬁbroblasts present in the ﬁbrotic lungs in
IPF, and that these populations respond differently to IL-6/gp130
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signaling. To determine the effect of hyperactive STAT3 signal-
ing and IL-6 on lung ﬁbrosis, an elegant study was performed
using transgenic mice containing a mutation in the common
IL-6 family receptor subunit, gp130, leading to polarized and
dysregulated STAT1/3 (gp130757F), or Erk1/2 (gp130Stat) sig-
naling upon receptor activation (O’Donoghue et al., 2012). When
challenged with bleomycin, the gp130757F transgenic mice exhib-
ited an increase in lung ﬁbrosis, COL1, and IL-6 expression
when compared to wild type, bleomycin-challenged mice. Also,
the knockdown of IL-6 (i.e., gp130757F; IL-6-/-) ameliorated the
observed ﬁbrotic response in these mice. Further, the pro-ﬁbrotic
role of IL-6 and its signaling pathway was examined in vivo using
the bleomycin model of lung ﬁbrosis in an IL-6-/- mouse (Saito
et al., 2007). In this study, there was a signiﬁcant reduction in
bleomycin induced lung ﬁbrosis in the IL-6-/- mouse as compared
to wild type mice.
Collectively, these studies indicate that IL-6 and IL-6 receptor
signaling play an important role in the ﬁbrotic response in IPF
and that there is a heterogeneous population of ﬁbroblasts with
skewed IL-6 signaling in IPF lungs leading to the pro-ﬁbrotic and
anti-apoptotic responses by these cells.
TLR9
The innate immune system plays a major role as a ﬁrst line of
defense against many pathogens by their sequestration and/or
destruction and clearance followed by the initiation of a regen-
erative healing response. To function rapidly and efﬁciently, the
innate immune system utilizes a class of receptors, called Pattern
Recognition Receptors (PRRs) to sense and react to proteins,
lipids, and nucleic acids released from the damaged host or acti-
vated inﬂammatory cells (Damage Associated Molecular Pattern
or DAMPs) or by the infecting pathogen (Pathogen Associated
Molecular Pattern or PAMPs). Currently, 10 Toll Like Receptors
(TLRs) have been identiﬁed in human (TLR 1-10), and 12 in mice
(TLR 1–9 and 11–13) with TLR 1–9 being the best characterized.
TLR1, 2, 4, 5, and 6 are expressed on the plasma membrane and
TLR 3, 7, 8, and 9 are predominantly expressed on the mem-
brane of the endoplasmic reticulum (ER) and are translocated
to endosomal membranes upon cellular activation where they
bind to microbial RNA and DNA. Most TLR ligands induce the
homodimerization [TLR 3, 4, 5, 6, 7 (in mouse), and 9] or het-
erodimerization (TLR1/ 2, TLR6/2, and TLR7/8 in human) of
TLRs to induce a cellular response.
Toll Like Receptor 9 is a member of the TLR family of PRR,
which recognizes hypo-methylated CpG containing DNA from
bacteria (Hemmi et al., 2000), viruses (Lund et al., 2003), and
mitochondria from damaged host cells (Zhang et al., 2010) and is
predominantly expressed by immune cells. It is primarily localized
in the membrane of the ER and is translocated into endosomes
upon cellular activation, where its cytoplasmic domain is pro-
teolytically modiﬁed by acid-dependent proteases to generate a
signaling receptor (Ewald et al., 2011).
Idiopathic pulmonary ﬁbrosis is characterized by the sustained
activation of myoﬁbroblasts and excessive deposition of ECM pro-
teins leading to the loss of the normal lung architecture. It is
thought that a low-grade chronic inﬂammatory response might
FIGURE 2 | Overview of IL6 signaling and regulation. Shown is a simpliﬁed
overview of IL6 signaling and regulation. IL6 signals through its receptor,
IL6αR, and GP130. The signal is then transduced through JAK1/2 and STAT1/3
and the SHP2/ERK MAPK pathways (not shown). IL6 signaling is regulated via
the action of several proteins and mechanisms including PIAS, SOCS, SHP2,
and the shedding of IL6Rα.
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contribute to the activation and proliferation of myoﬁbroblasts
and the enhanced ﬁbrotic response in IPF and thus there is great
interest in the role of PRR receptors such as TLR3 and TLR9
in this disease. IPF has been previously observed to progress
at different rates, with some patients showing slow progression
characterized by the gradual decline of lung functions (slow pro-
gressors) and other patients progressing at a faster rate with a rapid
decline of lung functions (rapid progressors). Recently, TLR9
expression was shown to be higher in untreated IPF as com-
pared to normal lung ﬁbroblasts and treatment of IPF but not
normal lung ﬁbroblasts with the Th2 cytokines IL-4 and IL-13
further increased its expression (Meneghin et al., 2008). Further,
ﬁbroblasts derived from rapid progressor IPF lung biopsies were
observed to have higher response to the TLR9 agonist, CpG-
ODN, as compared to ﬁbroblasts derived from slow progressor
IPF lung biopsies (Trujillo et al., 2010b), suggesting that TLR9
signaling is enhanced in rapid progressor ﬁbroblast and that this
PRR might contribute to the enhanced progression of IPF in rapid
progressor IPF patients. TLR9 activation by CpG-ODN treatment
induced the differentiation of IPF but not normal lung ﬁbrob-
lasts into myoﬁbroblasts as evident by increased αSMA expression
(Meneghin et al., 2008), induced the differentiation of TGF-β
treated blood monocytes into CD45+ αSMA+ COL1+ ﬁbrocytes,
and induced the Epithelial to Mesenchymal Transition (EMT)
of the type II alveolar epithelial cell line, A549 cells (Trujillo et al.,
2010b).
Recently, it was shown that there was a defect in miRNA pro-
cessing in rapid progressor lung ﬁbroblasts which the authors
hypothesized to be due to decreased expression of two proteins,
Argonaute RISC catalytic component 1 and 2 (AGO1 and AGO2,
respectively), which are essential components of the RISC complex
(Oak et al., 2011). In a subsequent study, CpG-ODN treatment
was observed to signiﬁcantly reduce AGO1 expression in rapid
progressor lung ﬁbroblasts, further supporting a role of TLR9
activation in the aberrant proﬁbrotic phenotype of IPF ﬁbroblasts
from rapid progressor IPF patients (Hogaboam et al., 2012).
The role of TLR9 in ﬁbrosis was further studied in vivo using
mouse models of lung ﬁbrosis. By intravenous injection of human
lung ﬁbroblasts into C.B-17SCIDmice, (Trujillo et al., 2010b) have
shown that ﬁbroblasts isolated from rapid progressor IPF lung
biopsies increased the ﬁbrotic response in the lung 63 days after
injection as compared to ﬁbroblasts isolated from slow progressor
IPF lung biopsies. Further, intranasal treatment with CpG-ODN
induced a signiﬁcant increase in lung ﬁbrosis in the rapid pro-
gressor but not the slow progressor ﬁbroblasts injected mice
further supporting the in vitro studies showing increased pro-
ﬁbrotic responses by these ﬁbroblasts in response to CpG-ODN
treatment. In another model of lung ﬁbrosis, it was observed
that the bleomycin induced lung ﬁbrosis was similar between
TLR9-/- and wild type mice; however, when bleomycin challenged
wild type mice were intranasally administered with CpG-ODN,
there was a reduction in lung ﬁbrosis as compared to untreated
bleomycin challenged wild type mice (Luckhardt et al., 2011). In
this study, the authors hypothesized that the observed reduction
in lung ﬁbrosis in response to CpG-ODN treatment is due to
the increased TLR9 induced Interferon-beta (IFN-β) expression,
which was shown to reduce lung ﬁbroblast proliferation. These
studies suggest that TLR9 responses in bleomycin-induced ﬁbro-
sis, amodelwhich is characterized by a strong inﬂammatory driven
ﬁbrotic response, are different from those observed in humanized
SCID model of pulmonary ﬁbrosis, a model which is primarily
driven by the injected human ﬁbroblasts and is largely inde-
pendent from any inﬂammatory responses, and that the role of
TLR9 in ﬁbrosis might be dependent on the surrounding cytokine
environment as evident by the different TLR9 induced response
observed in the inﬂammatory dependent and the inﬂammatory
independent murine pulmonary ﬁbrotic models.
Collectively, these studies suggest that TLR9 expression is
enhanced in lung ﬁbroblasts derived from rapid progressor IPF
lung biopsies and the activation of this receptor leads to increased
ﬁbrotic response of human lung ﬁbroblasts, the differentiation of
monocytes into ﬁbrocytes, and the EMT of alveolar type II cells
leading to dysregulated ECM production and the deterioration of
the normal lung architecture. However, future studies are war-
ranted to dissect the signaling pathways activated in IPF versus
normal lung ﬁbroblasts to CpG-ODN stimulation and the role of
other nucleic acid sensors in the response of these ﬁbroblasts to
microbial nucleic acids.
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